Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended On March 31, 2024
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 ,inter alia, to consider and approve audited financial results for the quarter and year ended on March 31, 2024 Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA for Dapsone Gel, 7.5% Zydus Lifesciences Ltd - 532321 - Update On Sale Of Stake Of Bayer Zydus Pharma Private Limited
Update on Sale of stake of Bayer Zydus Pharma Private Limited Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sentynl Therapeutics announces global acquisition of Zokinvy (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals. Zydus Lifesciences Ltd - 532321 - Sentynl Therapeutics Inc., USA, A Wholly Owned Subsidiary Of Zydus Lifesciences Limited Has Acquired Worldwide Proprietary Rights To Zokinvy(r)
Sentynl Therapeutics Inc., USA, a wholly owned subsidiary of Zydus Lifesciences Limited has acquired worldwide proprietary rights to Zokinvy Zydus Lifesciences Ltd - 532321 - Revised Disclosure For Disclosure Submitted On May 1, 2024
Revised disclosure for disclosure submitted on May 1, 2024 Zydus Lifesciences Ltd - 532321 - Revised Disclosure For Disclosure Submitted On May 1, 2024
Revised disclosure for disclosure submitted on May 1, 2024 Zydus Lifesciences Ltd - 532321 - Receipt Of A Demand Order-In-Original
Zydus Healthcare Limited, a wholly owned subsidiary has received a Demand Order-In-Original from Deputy State Tax Officer 1, Thiruvanmiyur Zydus Lifesciences Ltd - 532321 - Receipt Of A Demand Order-In-Original
Zydus Healthcare Limited, a wholly owned subsidiary has received a Demand Order-In-Original from Deputy Commissioner of State Tax, Durg, Chhattisgarh